Great Point Partners LLC Arvinas, Inc. Transaction History

Great Point Partners LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$36.38 - $52.31 $5.93 Million - $8.52 Million	-162,969 Reduced 69.62%	71,113 $2.94 Million
Q4 2023 Feb 14, 2024	BUY	$14.19 - $42.33 $3.32 Million - $9.91 Million	234,082 New	234,082 $9.63 Million
Q1 2021 May 17, 2021	SELL	$58.19 - $91.37 $9.55 Million - $15 Million	-164,150 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$20.19 - $84.93 $925,105 - $3.89 Million	45,820 Added 38.72%	164,150 $13.9 Million
Q1 2020 May 15, 2020	SELL	$33.0 - $54.5 $14.2 Million - $23.5 Million	-431,670 Reduced 78.49%	118,330 $4.77 Million
Q4 2019 Feb 14, 2020	BUY	$15.39 - $44.38 $8.46 Million - $24.4 Million	550,000 New	550,000 $22.6 Million

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.02B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Great Point Partners LLC with notifications on news.